CLIA Chlamydia pneumoniae IgA
Chemiluminescence kit for the detection of IgA antibodies to Chlamydia pneumoniae in human serum or plasma
Runs on
KleeYa® Automated CLIA Analyser
See the analyser and everything it runs
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
- Detection of IgA antibodies to Chlamydia pneumoniae
- Disease stage specification
- Intended for human serum and plasma
- The purified and inactivated antigen of C. pneumoniae used
Description
Chlamydiae are gram-negative bacteria, obligate intracellular parasites. Among them, Chlamydia pneumoniae is the most widespread species in the human population and can cause respiratory tract infections, such as pneumonia. In recent years, the number of acute and chronic infections has increased. The Primary infection usually occurs between 5 and 18 years of age. The typical clinical symptoms include rhinitis, sinusitis, otitis media, pharyngitis, bronchitis, atypical pneumonia with non-productive cough and indistinctive auscultatory findings. In the past 20 years, researchers have linked a wide variety of diseases to C. pneumoniae infection.
Technical data
- Assay stability: 30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
- Sample matrix: Serum, Plasma
- Sample volume: 10 μL
- Measuring range: 5 – 100 U/ml
- Complementary products: Anchor® Tips, Stackable Cuvette, KleeYa Trigger Pack, KleeYa Wash buffer
- Note: The kits are CE-IVD certified and intended for professional use.
Specifications
- Catalog Number: CL-CPA100
- Size: 100 tests
- Regulatory status: CE IVD
- Clinical topic: Infectious Diseases
- Diagnostic panel: COVID-19 Respiratory Diseases
- Producer: TestLine Clinical Diagnostics s.r.o.
References
- 7512399,2294050,3724806,10719781,11905590,12572892,15184423,8030740,7035557,2466791
- Hammerschlag MR. Pneumonia due to Chlamydia pneumoniae in children: epidemiology, diagnosis, and treatment. Pediatr Pulmonol. 2003 Nov;36(5):384-90. doi: 10.1002/ppul.10326. PMID: 14520720.
- Lieberman D, Lieberman D. Atypical pathogen pneumonia. Curr Opin Pulm Med. 1997 Mar;3(2):111-5. doi: 10.1097/00063198-199703000-00005. PMID: 9193855.
- Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010 Jan 15;50(2):202-9. doi: 10.1086/648678. PMID: 20014950; PMCID: PMC7107844.
- Hammerschlag MR, Reznik T, Roblin PM, Ramirez J, Summersgill J, Bukofzer S. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother. 2003 Apr;51(4):1025-8. doi: 10.1093/jac/dkg154. Epub 2003 Feb 25. PMID: 12654764.
- Peeling RW. Laboratory diagnosis of Chlamydia pneumoniae infections. Can J Infect Dis. 1995 Jul;6(4):198-203. doi: 10.1155/1995/696950. PMID: 22514397; PMCID: PMC3327923.
- Villegas E, Sorlózano A, Gutiérrez J. Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives. J Med Microbiol. 2010 Nov;59(Pt 11):1267-1274. doi: 10.1099/jmm.0.020362-0. Epub 2010 Aug 19. PMID: 20724512.
- Reagent Cartridge with specific reagents for the assay
- magnetic particles
- calibrators
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Safety information
Product brochure
Declaration of conformity
EC Certificate
Frequently paired with this kit
Other assays and instruments lab teams add alongside the CLIA Chlamydia pneumoniae IgA.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
